Current and historical daily PE Ratio for Biomarin Pharmaceutical Inc (
) from 1999 to Apr 23 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Biomarin Pharmaceutical stock (BMRN) PE ratio as of Apr 23 2024 is 104.61.
More Details
Biomarin Pharmaceutical Inc (BMRN) PE Ratio (TTM) Chart
Biomarin Pharmaceutical Inc (BMRN) PE Ratio (TTM) Historical Data
View and export this data going back to 1999. Start your Free Trial
Total 1213
- 1
- 2
- 3
- 4
- 5
- 6
- 14
| Biomarin Pharmaceutical PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-23 | 104.6 | 2024-02-16 | 100.9 |
| 2024-04-22 | 101.7 | 2024-02-15 | 100.3 |
| 2024-04-19 | 100.7 | 2024-02-14 | 97.7 |
| 2024-04-18 | 102.3 | 2024-02-13 | 97.9 |
| 2024-04-17 | 102.8 | 2024-02-12 | 100.2 |
| 2024-04-16 | 103.3 | 2024-02-09 | 100.5 |
| 2024-04-15 | 104.0 | 2024-02-08 | 100.2 |
| 2024-04-12 | 104.8 | 2024-02-07 | 101.9 |
| 2024-04-11 | 103.9 | 2024-02-06 | 102.0 |
| 2024-04-10 | 102.5 | 2024-02-05 | 99.7 |
| 2024-04-09 | 101.1 | 2024-02-02 | 100.1 |
| 2024-04-08 | 99.2 | 2024-02-01 | 100.8 |
| 2024-04-05 | 98.8 | 2024-01-31 | 100.1 |
| 2024-04-04 | 98.7 | 2024-01-30 | 101.8 |
| 2024-04-03 | 98.6 | 2024-01-29 | 104.3 |
| 2024-04-02 | 98.6 | 2024-01-26 | 103.3 |
| 2024-04-01 | 99.0 | 2024-01-25 | 103.7 |
| 2024-03-28 | 99.3 | 2024-01-24 | 104.9 |
| 2024-03-27 | 100.7 | 2024-01-23 | 105.7 |
| 2024-03-26 | 99.7 | 2024-01-22 | 106.9 |
| 2024-03-25 | 98.3 | 2024-01-19 | 104.8 |
| 2024-03-22 | 96.7 | 2024-01-18 | 105.2 |
| 2024-03-21 | 95.6 | 2024-01-17 | 106.2 |
| 2024-03-20 | 96.3 | 2024-01-16 | 106.2 |
| 2024-03-19 | 96.9 | 2024-01-12 | 106.1 |
| 2024-03-18 | 95.2 | 2024-01-11 | 109.1 |
| 2024-03-15 | 95.3 | 2024-01-10 | 109.0 |
| 2024-03-14 | 95.9 | 2024-01-09 | 109.2 |
| 2024-03-13 | 96.3 | 2024-01-08 | 112.5 |
| 2024-03-12 | 96.8 | 2024-01-05 | 109.6 |
| 2024-03-11 | 97.7 | 2024-01-04 | 111.1 |
| 2024-03-08 | 97.7 | 2024-01-03 | 109.9 |
| 2024-03-07 | 97.6 | 2024-01-02 | 111.4 |
| 2024-03-06 | 98.6 | 2023-12-29 | 109.6 |
| 2024-03-05 | 97.8 | 2023-12-28 | 110.4 |
| 2024-03-04 | 99.7 | 2023-12-27 | 127.3 |
| 2024-03-01 | 99.0 | 2023-12-26 | 125.4 |
| 2024-02-29 | 98.0 | 2023-12-22 | 125.1 |
| 2024-02-28 | 100.5 | 2023-12-21 | 123.8 |
| 2024-02-27 | 103.0 | 2023-12-20 | 120.5 |
| 2024-02-26 | 102.4 | 2023-12-19 | 125.5 |
| 2024-02-23 | 103.7 | 2023-12-18 | 125.2 |
| 2024-02-22 | 102.2 | 2023-12-15 | 126.3 |
| 2024-02-21 | 100.6 | 2023-12-14 | 126.9 |
| 2024-02-20 | 100.8 | 2023-12-13 | 128.1 |
Biomarin Pharmaceutical Inc (BMRN) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Biomarin Pharmaceutical Inc
NAICS : 325412
SIC : 2834
ISIN : US09061G1013
Share Class Description:
BMRN: Registered SharesCompare
Compare
Traded in other countries / regions
BMRN.USABMRN.MexicoBMRN.AustriaBM8.Germany1BMRN.ItalyB1MR34.Brazil0HNC.UK IPO Date
1999-07-23Description
BioMarin's focus is on rare-disease therapies. Genzyme (now part of Sanofi) markets Aldurazyme through its joint venture with BioMarin, and BioMarin markets Naglazyme, Vimizim, and Brineura independently. BioMarin also markets Kuvan and Palynziq to treat the rare metabolic disorder PKU. Voxzogo (vosoritide) was approved in achondroplasia in 2021. BioMarin's Roctavian (hemophilia A gene therapy) was approved in Europe in 2022 and in the US in 2023.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers